title: Beneficial effect of beraprost sodium plus telmisartan in the prevention of arterial stiffness development in elderly patients with hypertension and cerebral infarction.
abstract: Beraprost sodium (BPS, an analogue of prostacyclin) and telmisartan (TS, an angiotensin receptor blocker) have been reported to have a preventive effect on arterial stiffness in patients with cardiovascular diseases. The purpose of this study was to estimate the effects of a combined therapy using BPS and TS on arterial pulse wave velocity (PWV) values in elderly patients with hypertension and cerebral infarction. Over a 3-month period, 80 subjects with hypertension and histories of cerebral infarction received BPS only (120 microg/day p.o.), TS only (40 mg/day p.o.), both BPS and TS, or no medication at all (control). Arterial PWV and ankle brachial indices (ABI) were determined prior to and after 3 months of drug administration. During the follow-up, there were no significant changes in any of the parameters monitored with the exception of a significant decrease in systolic blood pressure in the BPS only, TS only, and BPS plus TS groups when compared to controls. The difference values for PWV in the control group, BPS only group, TS only group, and BPS plus TS group were +232.5, -114.6, -151.5, and -248.1 cm/s, respectively. The reduction values were significantly more pronounced in the BPS plus TS group than in the BPS only (P=0.037) and the TS only (P=0.022) groups. When BPS is combined with TS, an overall additive effect is seen in the improvement of PWV in Japanese patients with hypertension and cerebral infarction. This combination therapy is more beneficial than the corresponding monotherapies.
authors.affiliation: Division of Molecular Diagnostics, Department of Advanced Medical Science, Nihon University School of Medicine, Ooyaguchi-kamimachi, 30-1 Itabashi-ku, and Itabashi-ku Hospital, Tokyo 173-8610, Japan. tnakayam@med.nihon-u.ac.jp
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Nakayama
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Masubuchi
authors.forename: Kazunori
authors.initials: K
authors.lastname: Kawauchi
authors.forename: Riko
authors.initials: R
authors.lastname: Masaki
authors.forename: Takashi
authors.initials: T
authors.lastname: Hironaga
authors.forename: Hatsue
authors.initials: H
authors.lastname: Ishima
authors.forename: Mami
authors.initials: M
authors.lastname: Torigoe
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Shimabukuro
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D001161:Arteriosclerosis / Q000150:complications / Q000517:prevention & control*; D001562:Benzimidazoles / Q000627:therapeutic use*; D001565:Benzoates / Q000627:therapeutic use*; D001783:Blood Flow Velocity; D002544:Cerebral Infarction / Q000150:complications*; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D011464:Epoprostenol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006973:Hypertension / Q000150:complications*; D008297:Male; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D000077333:Telmisartan; D016896:Treatment Outcome
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D001562:Benzimidazoles; D001565:Benzoates; D010975:Platelet Aggregation Inhibitors; C048081:beraprost; D011464:Epoprostenol; D000077333:Telmisartan